Primary lung tumors, breast tumors, and melanoma metastasize mainly in the brain where therapy is limited to surgery and radiation. To investigate the molecular basis of brain metastases, we isolated brain-trophic metastatic MDA-MB-435-LvBr2 (LvBr2) cells via left ventricle (LV) injection of MDA-MB-435 cells into immunodeficiency (NOD/ SCID) mice. Whereas parent MDA-MB-435 cells displayed an elongated morphology, LvBr2 cells were round and displayed an aggregated distribution. LvBr2 cells expressed lower β-catenin levels and higher heterogeneous nuclear ribonucleoprotein C1/C2 (hnRNPC) levels than parental cells. Since microRNAs are known to play an important role in cancer progression including metastasis, we screened microRNAs expressed specifically in brain metastases. MicroRNA-146a was almost undetectable in LvBr2 cells and highly expressed in the parental cells. Overexpression of miR-146a increased β-catenin expression and suppressed the migratory and invasive activity of LvBr2 cells. The miR-146a-elicited decrease in hnRNPC in turn lowered the expression of MMP-1, uPA, and uPAR and inhibited the migratory and invasive activity of LvBr2 cells. Taken together, our findings indicate that miR-146a is virtually absent from brain metastases and can suppress their metastatic potential including their migratory and invasive activities associated with upregulation of β-catenin and downregulation of hnRNPC.
INTRODUCTION
Despite great efforts to develop cancer therapies, cancer mortality has been on the rise, which is due to metastasis rather than to primary tumor itself (Nguyen et al., 2009) . Metastasis has been recognized as the main cause of recurrence and poor prognosis. The metastatic process involves multiple genes which enable cells to enter the bloodstream, disseminate, adapt to new miroenvironments, and proliferate at distant organs (Chambers et al., 2002) . Although brain metastases are highly aggressive, they can only be treated using surgery and radiation. Metastasis of melanoma cells to lymph nodes, liver, lung, and brain constitutes a major cause of death (Akslen et al., 1987) . In the case of brain metastasis, the prognosis of melanoma patients is very poor and median survival is less than 6 months. Moreover, despite of advanced therapies, treatment options for brain metastatic melanoma are restricted and their efficiency is very low.
With the discovery of oncogenic and tumor suppressive miRNAs, aberrant expression of miRNAs has been implicated in the malignancy of cancer cells. Many miRNAs are found to regulate metastatic processes including epithelial-to-mesenchymal transition (EMT), adhesion, migration, invasion, apoptosis, angiogenesis, and colonization (Hurst et al., 2009 ). Metastasis-associated miRNAs (Metastamir) are categorized into metastasis-suppressing and metastasis-promoting miRNAs (Aigner, 2011; Hurst et al., 2009; Nicoloso et al., 2009 ) and their functions have been investigated in variety of cancer cells. MiR-146 is reported to enhance proliferation and inhibit apoptosis of gastric cancer cells (Xiao et al., 2012) and to diminish the metastatic potential of breast cancer cells by targeting IRAK1 and TRAF6, which suppress invasiveness of pancreatic cancer cells via positive regulation of NF-κB (Bhaumik et al., 2008; Li et al., 2010) .
In the present report, we studied brain metastasis-specific miRNAs using a xenograft model. We found that brain-trophic metastatic LvBr2 cells expressed higher level of proteolytic enzymes than parent MDA-MB-435 cells. Of 97 miRNAs whose expression was significantly changed in brain metastasis, miR-146a showed potently decreased expression in brain metastasis and its overexpression suppressed the metastatic potential of LvBr2 cells, which is linked to the upregulation of βcatenin and the downregulation of hnRNPC. 
MATERIALS AND METHODS
Xenograft model for brain metastasis and miRNA microarray Brain-trophic metastatic MDA-MB-435 cells were isolated previously after serial injection of MDA-MB-435 cells through the left ventricle (LV) of heart (Nam et al., 2008) . We termed these brain-trophic metastatic cells as MDA-MB-435-LvBr1 (LvBr1, first cycle) and MDA-MB-435-LvBr2 (LvBr2, second cycle). To rule out the effect of the brain microenvironment, MDA-MB-435-IcBr cells (IcBr) were isolated from brain lesions performed by intracranial (IC) injection of MDA-MB-435 cells. Since LvBr1 and LvBr2 cells showed very similar results, here we represented the results obtained using LvBr2. Total RNA was isolated using Trizol (Invitrogen) and used for microRNA microarray (Affymetrix GeneChip ® microRNA microarray).
Cell culture and transfection MDA-MB-435, LvBr1, LvBr2, and IcBr cells were maintained at 37°C, 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Hyclone) supplemented with 10% fetal bovine serum (GIBCO-BRL) and 1% antibiotic-antimycotic solution (GIBCO-BRL). Cells were transfected using lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. HnRNPC siRNA was from Santa Cruz Biotechnology and control siRNA (CTRL) from Genolution (Korea). Precursor miR-146a (pre-miR-146a, Ambion) was used to overexpress miR-146a.
Reagents and antibodies
Cycloheximide was from Sigma Aldrich. The antibodies were as follows: anti-hnRNPC and anti-EGFR were from Santa Cruz Biotechnology; anti-Flag was from Sigma Aldrich, and antiphospho-Akt, anti-Akt, anti-phospho-ERK, and anti-ERK from Cell Signaling Technology. Anti-GAPDH, anti-ST6GALNAC5, and anti-E-cadherin were from Abcam.
Western blot and quantitative real-time PCR
For Western blot analysis, proteins were fractionated and then transferred to PVDF membrane (Millipore). Membranes were incubated with primary antibodies and HRP-conjugated secon-dary antibodies, and visualized using enhanced chemiluminiscence (ECL, Amersham). For reverse transcription (RT) and quantitative (q) real-time PCR analysis, total RNA was isolated using Trizol (Invitrogen) according to the manufacturer's procedure. The level of mRNA expression was determined using power SYBR ® Green PCR Master Mix (Applied Biosystems, USA). Primer sequences are listed in Supplementary Table 1 . The level of GAPDH mRNA was used as internal control for normalization.
Migration and invasion assay
Migratory activity was determined by measuring cells with the ability to cross the pores of migration chambers in the presence of chemoattractants (10% FBS). Briefly, equal numbers of starved cells were added onto the upper chambers of 24-well Falcon Cell Culture Transwells (8 µm pore, QCM Colorimetric Cell Migration Assay kit, Millipore). Migration of cells was initiated by adding serum-containing media into the lower chamber; 24 h later, the migrated cells were stained with crystal violet and the migratory activity was determined by measuring the optical density at 560 nm. For invasion assay, Matrigel Transwells (BD Biocoat Matrigel Invasion Chamber) were used. Equal numbers of cells were added to the upper chamber and cells were allowed to invade by adding fresh DMEM containing 10% fetal bovine serum into the lower compartment. Invading cells were fixed and stained with hematoxylin/eosin (H/E) and the number of invading cells on the lower surface of the membrane was counted under a microscope in several fields.
RESULTS
Brain-trophic metastatic LvBr2 cells showed higher metastatic activity than parent MDA-MB-435 cells MDA-MB-435 cells were reported to form brain metastasis by injection into the left ventricle (LV) of heart or the internal carotid artery (ICA) (Nam et al., 2008; Price et al., 1990) . To investigate the role of miRNA in brain metastasis, MDA-MB-435-LvBr cells were isolated from brain metastasis cells after serial LV injection of parent MDA-MB-435 cells (LvBr1 cells were obtained from the first cycle and LvBr2 cells from the second cycle). 
